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Abstract 
 
Development of in-vitro 3D cellular disease models is emerging at a fast pace. 2D culture 
systems are limited due to minimal cell-cell interactions and poor stromal intervention. Cells in 
2D monolayer receive uniform oxygenation and nutrition in contrast to hypoxic conditions of in-
vivo tumors. Hence, there is a need to develop 3D models which are more physiologically 
relevant than 2D models & improves the prediction of drug candidates. 3D models possess more 
realistic multicellular complexity (cell-cell, cell-matrix interactions) and mimics in-vitro 
microenvironment more closely. Present study delineates the development of a novel in-vitro 3D 
cancer model by incorporating cancer aggregates into porous scaffolds. This serves as a portable 
lab-on-a-chip platform for screening antitumor chemotherapeutic agents, For this purpose, 
gelatin–chitosan scaffolds were prepared by freeze-drying method, crosslinked using 
glutaraldehyde and investigated for their physical & functional characteristics such as micro 
architecture (SEM), FTIR, XRD, swelling property, degradation kinetics (using lysozyme) and 
biocompatibility. Microtissue comprising cervical cancer cells (HeLa) was prepared by 
suspending cancer cells in a hanging drop of culture medium followed by gravity enforced self 
assembly of cells into a solid mass. This cancer aggregate was embedded into the prepared 
porous scaffolds and cultivated in standard culture conditions. Microtissue viability in the 3D 
microenvironment of polymeric scaffold was assessed by MTT assay. Cryopreservation 
performance of microtissue seeded scaffold construct was examined by cooling using liquid N2. 
Resuscitation of the constructs by thawing after 2 days of cryopreservation showed that system 
retained 76% of cell viability and metabolic activity. The constructs were then used as a cancer 
tissue mimetic to compare the efficacy of two anticancer drugs namely Fluorouracil (5-FU) and 
Cisplatin. Not all cells of the microtissue are exposed to the same drug concentration due to poor 
drug diffusion through the biomimetic scaffold which resembles native ECM. As predicted, 
percentage cell death is less in case of our model compared to conventional monolayer culture. 
These results clearly imply that the proposed gelatin-chitosan scaffold based 3D cancer model 
closely mimics in-vivo tumor conditions and can be used as an in-vitro screening system for 
anticancer drug screening.  
 
Keywords: 2D, 3D model; cancer; chitosan; cisplatin; cryopreservation; lab-on-a-chip; gelatin; 
fluorouracil; HeLa cells; microtissue; scaffold 
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1.1 Introduction 
Cancer refers to abnormal growth of cells without control, ultimately evolving into a population 
that can invade other tissues by metastasis. It is one of the most serious diseases with millions of 
people who have cancer or have died because of its devastating effects. There are more than 
hundred different types of cancer. It is one of the most challenging disease of all - not only in 
terms of clinical barriers to its sufferers, but also to pharmaceutical companies and manufacturers 
who attempt to discover promising anticancer drugs.  
Discovery and development of anticancer agents is the central focus of many pharmaceutical 
companies and other organizations, like the National Cancer Institute (NCI) [1]. Despite 
numerous efforts, successful development of cancer therapy is hindered by insufficient 
understanding of tumorigenesis. Anticancer drug development efforts focus on cytotoxic 
compounds that cause tumor termination. Recent spurt in the understanding of cancer 
pharmacology has facilitated the development of target-based drugs that are designed to 
selectively inhibit molecular markers involved in cancer growth and metastasis.  
Once potential cytotoxic compounds are obtained by chemical synthesis or extraction from 
natural sources, the subsequent stages involved in drug development process are as follows: 
1. Preliminary in-vitro screening: In-vitro cell culture models are used to evaluate anti-
tumorigenic activity of new drug candidates. Approximately 10000 drugs are tested in in-vitro 
models on a yearly basis to investigate the extent and specificity of anti cancerous activity.  
 
2. Pre-clinical in-vivo testing: Evaluation of drug toxicity and efficacy in animals. 
 
3. Clinical Development: Drug toxicity is tested in human volunteers to identify maximum 
tolerated dose in phase I clinical trials. To quantify efficacy and to confirm drug dosage, phase II 
studies are conducted in patients of selected tumor type followed by massive phase III studies.  
 
This entire process of drug discovery and development is innately time and resource  
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consuming with very low success rates. Out of 10,000 drugs screened, often only 100 are tested 
in pre-clinical research, 5-10 enter clinical trials and finally, only 1 or 2 compounds are 
eventually approved by NDA as marketed drug for treatment. The average time starting from a 
new compound synthesis to obtain market approval is approximately 9 to 12 years with average 
costs ranging from 0.5 to 2 billion US$ depending on the disease.   
 
Fig.1  Drug Discover Pipeline. (PhRMA - The Pharmaceutical Research and Manufacturers of America, 
IND - Investigational New Drug ) 
 
Preclinical and clinical drug development has predominantly relied on animal systems. The time 
and costs of drug development significantly increases during pre-clinical in-vivo testing using 
animals and further more in subsequent clinical trials, it is pivotal to identify promising drug 
leads accurately in the early stages of drug development [2]. Successful selection and 
development of the most active drug candidates requires reliable and robust in-vitro test systems. 
Novel approaches have been adopted for creating dependable in-vitro models that mimic in-vivo 
tumor behavior. Complex interaction between multiple cell types operating within the 3D tissue 
ECM microenvironment is highly critical for tissue development, homeostasis and tumor 
pathogenesis. Gene expression, invasive behavior of many human carcinomas are sensitive to 
'solid factor signals' and behaves entirely different in the presence or absence of stroma. Existing 
in-vitro models include - 2D monolayer culture and 3D spheroid models. 
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Fig 2 Outline of drug discovery process focusing on current strategies employed for preclinical testing of 
antitumor drug candidates (Kunz Schughart et al. 2010) 
 
1.2 Conventional tumor models 
 
2D Monolayer: Cells cultivated directly on 2D tissue culture plates differ substantially in their 
morphology, cell-cell interactions, cell-matrix interactions and differentiation from those grown 
in 3D microenvironment. 2D models differ from in-vivo tumor conditions in the following ways: 
i) Gene expression profile in 2D systems often differs from in vivo conditions, because of two 
dimensional cellular organization & limited cell-cell interactions. 
ii) Passive transport of nutrient and excretory products is sufficient in 2D system, for 
maintenance of normal pathophysiology. However, such over simplified mass transfer do not 
hold true in in-vivo conditions. 
iii) In contrast to hypoxic environment of in-vivo tumors, uniform nutrition and oxygenation is 
provided to monolayer cells.  
iv) Lack of in-vivo like dense stroma in 2D monolayer which exhibits low IC50 of drugs 
pertaining to complete bioavailability of drug candidates to the target cells. However, IC50  
values of drugs in in-vivo tumors are comparatively higher.  
These differences demonstrate low in-vivo predictivity from 2D cell culture systems. 
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3D Spheroids: Spheroids refer to in-vitro aggregate of cells established either from a single 
cell type or from a mixture of multiple cell types: tumor cells, immune cells, epithelial cells, 
fibroblast cells, mesenchymal stem cells (MSCs) and endothelial cells. These aggregates are 
more effective than 2D systems because like tumors, spheroids usually contain a mixed 
population of surface-exposed and deeply buried cells, proliferating and non proliferating cells, 
well-oxygenated and hypoxic cells [3]. Though it maximizes cell-cell interactions, it inherently 
lacks stromal intervention. The average time required for a tumor spheroid to advance from an 
aggregate of few cells to an enlarged structure with viability and proliferative gradients ranges 
from 1 to 2 weeks. It is highly challenging to obtain spheroids of uniform size in a reproducible 
manner. 
 
                        
    Fig.3  2D Monolayer                         Fig.4   3D Spheroid                      Fig.5 Use of animals for research     
                                
An apparent solution to the above models is to use in-vivo animal models.  
 
Animal Models: Though scientific values and ethics of using animals for research are 
continuously being questioned, it is estimated that millions of animals are still widely used in 
variety of different research projects every year. Though, in vivo models address some of the 
limitations of in-vitro systems, ethical concerns, long experimental duration and non-human 
biology represents significant disadvantages. Besides, drugs and procedures that seem promising 
in animal models have often failed in early or later phases of clinical trials. Besides the cost of 
drug development increases substantially during pre-clinical in-vivo animal testing. Hence, we 
need to Reduce, Replace and Refine the use of animals. One of the elemental problems is low 
predictivity from currently employed preclinical research models. For economic and ethical 
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concerns, this necessities the development of 3D cancer models which overcome the gap 
between traditional 2D monolayer and animal models. 
 
1.3 In vitro 3D tumor models:  
 
It is highly essential to identify poor drug candidates in early stages of testing than later which 
would save both time and money. To optimize accurate selection of the most active drug 
molecules from the enormous and growing pool of compounds, test systems that closely simulate 
an in vivo solid tumor are highly essential.  
 
Hence, we need to create more realistic in-vitro cell culture models which faithfully replicates in-
vivo microenvironment. However, the realization of thick and viable disease equivalents in vitro 
is one of the major challenges in tissue engineering [4]. A biological tissue is not just a 
combination of cells within a bundle of inert macromolecules, but it is rather an intricate 
complex of cell and cell-synthesized matrix regulated by homeostatic equilibrium. Cells are 
regulated and controlled by the ECM composition and structure, which, in turn, are synthesized, 
assembled and remodeled by cells. Tissue dysfunction even when arisen from cellular 
components affects the extracellular space and vice versa [4]. Therefore, a reliable in-vitro 3D 
cancer model should reproduce the whole tissue, including the ECM assembly in order to 
faithfully and realistically mimic both the physiological and pathological status of in-vivo 
cancerous tissue. 
 
In-vitro 3D cancer models mimicking biologically important parameters of in-vivo 
microenvironment such as cell−cell, cell−ECM interactions will be a valuable device to examine 
the therapeutic efficacy of anticancer drugs [5]. 3D models are increasingly been used to 
accurately reproduce characteristics and behavior of human cancerous tissues. Novel strategies 
are being employed for creating better reliable in-vitro models that better recapitulate in-vivo 
conditions for testing the anti tumorigenic efficacy of anticancer drugs. These models also have 
the potential to improve and to optimize drug delivery systems for effective chemotherapy.  
 
The importance of in-vitro 3D tumor models has been widely recognized and their development  
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is emerging at a fast pace. Crystal S. Shin et al have adapted hydrogel template to culture 
spheroids in a hydrogel scaffold containing micro wells and subsequently transferred the 
spheroids to a microfluidic channel representing in-vivo dynamic fluid movement [5]. Hui-li Ma 
et al have demonstrated the capability of HeLa cell-derived spheroids to function as a screening 
tool for nanoparticle which act as delivery vehicles for chemotherapeutics [6]. They have 
reported three dimensional imaging of nanoparticle penetration into HeLa spheroids using HeLa 
cells grown in 2D culture as the control system. Moutushy Mitra et al have fabricated surface 
engineered, polymeric  biodegradable microparticles to be used as a scaffold for 3D growth of 
Y79 cell line in order to evaluate the effect of anticancer drugs [7]. Qgyi He et al have tissue 
engineered a pancreatic cancer model using pancreatic cancer stem cells delivered from a well 
defined electrospun scaffold of poly(glycolide-co-trimethylene carbonate) and gelatin [8].  Agata 
Nyga et al have constructed a novel colorectal cancer model using HT29 cells embedded in 
collagen type I which is encapsulated in a non-dense collagen type I gel populated by a mixture 
of fibroblasts and endothelial cells [9]. Jayme L. Horning et al have developed a breast cancer 
model by cultivating MCF-7 cells on porous, biodegradable polymeric microparticles [10]. 
Chandraiah Godugu et al have reported a 3D culture system for formation of spheroids in 
AlgiMatrix
TM
 scaffolds and subsequent cytotoxicity evaluation of anticancer drugs [11]. 
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2.1 Rationale of the work :  
 
The present study was conducted to develop a viable lab-on-a-chip 3D cancer equivalent with 
high in-vivo like characteristics and better predictivity than 2D monolayer and 3D spheroid 
models. Spheroids are more physiologically relevant than 2D monolayer as they overcome the 
limitations of 2D systems by maximizing cell-cell interactions. However, they lack stromal 
intervention which provides tumor promoting microenvironment highly essential for tumor 
growth, invasion and metastasis. Hence, spheroid models alone fail to mimic in-vivo tumor 
microenvironment. As an improvement over existing cancer models, we have proposed a novel 
3D cancer model by incorporating tumor like aggregates in a porous biomimetic scaffold. Cell-
cell interactions within the aggregate and cell-matrix interactions between the scaffold and 
aggregate forms a complex network of biochemical and mechanical signals, which are critical for 
tumor physiology. We have tried to address the relevance and potential of this 3D cancer model 
in drug discovery and development, with a focus on screening anticancer drugs. Furthermore, we 
have also proposed to assess the cryopreservation feasibility of this model to investigate its 
ready-to-use application in evaluating drug efficacy and toxicity after resuscitation. This 
innovative simplified preclinical approach will offer faster reliable results with far greater in 
vitro predictive  power. 
 
2.1.1 Choice of Biomaterials for scaffold fabrication:  
Scaffold acts as an artificial ECM and provides structural and biochemical support to cells until 
the cell produced ECM (collagen) takes over its function. This study demonstrates the use of 
porous 3D gelatin-chitosan scaffolds as a tissue culture model for supporting the growth of 
microtissue.  Chitosan has gained a lot of attention as a promising biomaterial in tissue 
engineering due to its large-scale availability, low cost, biocompatibility and anti-microbial 
activity [12]. Chitosan backbone mimics glycosaminoglycans (GAGs) structure, a major 
component of the native ECM. Chitosan is blended with other polymers in order to improve  its 
biological, mechanical and physiological property. To improve the biological activity of 
chitosan, gelatin (collagen mimic) is used since it (i) contains Arg–Gly–Asp (RGD)-like 
sequence which promotes cell adhesion and migration and (ii) forms a polyelectrolyte complex 
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[12]. Gelatin-chitosan scaffolds have been fabricated using crosslinkers such as glutaraldehyde, 
EDC-MES. Constructs formed upon embedding microtissue into these biomimetic scaffolds 
provides a reliable and cost-effective an vitro platform for evaluating the efficacy of anticancer 
drugs.  
 
2.1.2 3D Microtissue: 
Microtissue or microscale spheroids are relevant constructs for tissue engineering applications to 
evaluate toxicities of anticancer drugs.. Formed from cancer cells in hanging drops, microtissue 
mimics a tumor in vitro. Cytology and morphology of micro- or millimeter tumor microtissues 
bears a resemblance to in-vivo grown avascular tissue or natural human tumors before 
neovascularization with diffusional limitations. Three-dimensional tumor microtissues acquire 
resistance to apoptosis-inducing drugs that mimics chemoresistance of solid tumors. 
Furthermore, microtissues can be  handled easily in a cost-effective manner and are a faithful 
replica of native cancerous tissue. 3D tumor microtissue bridges the gap between in-vitro 2D cell 
assay and in-vivo animal models and offer powerful reliable in-vitro test systems for 
investigating compound efficacy and toxicity.  
 
2.1.3 Lab-on-a-chip device: 
Lab-on-a-Chip (LOC) is a device which integrates various laboratory functions such as 
separation and analysis of components of a mixture on a single microchip. It uses small fluid 
volumes in the order of microliters to nanoliters. The main commercial application of LOCs is in 
biotechnology and medical fields, where it can be used as novel microsensing systems. This is a 
newer cell based approach which merges microfluidics and imaging tools with modern tissue 
engineering by integrating in vitro produced pieces of cancer tissue mimic on microfluidic chips. 
The chip holds an array of microwells each comprising cancer microtissue embedded in a 
biomimetic scaffold mimicking cancer microenvironment. This portable, easy-to-use chip 
miniaturizes testing system and enables rapid, reliable and cost-effective assessment of the 
antitumorigenic effect of any given chemotherapeutic compound.  
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2.1.4 Anticancer drugs: 
Two most commonly used drugs: 5-Fluorouracil (5-FU) and Cisplatin were used in our analysis. 
Both these drugs are often used to treat various types of cancers.  
 
5-Fluorouracil (5-FU): a conventional anticancer drug which has been used against various 
types of cancers for many years. It is principally a suicide inhibitor of thymidylate synthase (TS), 
a nucleoside required for DNA replication. Deoxyuridine monophosphate (dUMP) is methylated 
by Thymydylate synthase to form thymidine monophosphate (dTMP). dTMP deficiency caused 
upon administrating 5-FU triggers apoptosis of rapidly dividing cancerous cells.  
 
Cisplatin: is a conventional chemotherapy drug particularly effective against testicular cancer. It 
binds to DNA and causes it to crosslink, subsequently interferes with the process of cell division 
by mitosis. DNA repair mechanism is activated by the damaged DNA, which in turn triggers 
apoptosis when repair seems impossible.   
 
 
2.2 Objective: 
 
To develop an in-vitro 3D cancer model that replicates in-vivo tumor behavior to be used as a 
screening tool to evaluate chemotherapeutic efficacy of anticancer drugs.  
 
1. Preparation of Lab-on-a Chip platform  
2. Fabrication of suitable tissue mimicking 3D scaffold  
3. Preparation of cancer microtissue 
4. Preparation of corresponding cancer tissue construct on lab-on-a-chip platform  
5. Evaluation of the model as anticancer drug screening system. 
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2.3 Work plan:  
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2.4 Design of the Proposed Model:  
 
 
 
Fig.6 Design of the Proposed Lab-on-a-chip 3D Cancer Model  
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3.1 Materials 
Gelatin (from bovine skin) and chitosan were procured from SIGMA ALDRICH.  
Glutaraldehyde (25% aqueous solution) was purchased from LOBAL CHEMIE (Laboratory 
Reagents & Fine Chemicals). For cell culture, DMEM, MEM, Dulbecco’s Phosphate Buffer 
Saline (DPBS), Trypsin-EDTA solution, FBS, antibiotic-antimycotic solution, and MTT assay 
kit were purchased from Himedia, Mumbai, India. For cell lysis IP lysis buffer Pierce was 
procured from Thermo scientific. Millipore water was used throughout the study. 
 
3.2 Cell culture 
HeLa (cervical cancer) cell line were cultured in flasks coated with gelatin and maintained in 
complete medium consisting of Minimal Essential Media (MEM) supplemented with 10% Fetal 
Bovine Serum (FBS) and 1% antibiotic-antimycotic cocktail in a humidified (95%), CO2 
incubator (5%) at 37
o
C. When the cells reached about 70% confluence, they were harvested by 
dissociating cells using 0.25% Trypsin-EDTA solution, followed by centrifugation of the 
dissociated cells at 1000 rpm for 10 minutes, and re-suspended in complete media. Cell density 
was estimated using a hemocytometer. HaCaT cell line was maintained in Dulbecco’s Minimal 
Essential Media (DMEM) following the same protocol.   
 
3.3 Preparation of Lab-on-a-chip device 
Polypropylene sheet was cut into chips of dimension 6 cm X 2.4 cm. The chips were thoroughly 
washed in Triton-X solution and then immersed in 70% ethanol solution for 10 minutes. They 
were then dried and micro wells were attached using poly-dimethylsiloxane (PDMS). The 
assembly was then baked at 65
o
C in a hot air oven for 1 hour. The PDMS gets spontaneously 
adhered to the plastic chip thus maintaining a tight sealing. In this way, microwell arrays were 
fabricated onto the chips.  
 
3.4 Scaffold Fabrication: 
2% gelatin solution was prepared by mixing gelatin in Millipore water on a magnetic stirrer at 
50 °C for 30 min. 2% Chitosan solution was prepared by dissolving chitosan in 1 vol.% acetic acid 
at room temperature. Three different compositions of mixture were prepared - (Gelatin: 
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Chitosan 1:1, 1:2, 2:1). The solutions were thoroughly mixed to have required weight ratio of 
gelatin to chitosan by stirring at 50 °C for 30 min until a homogeneous mixture was obtained. 
0.025% glutaraldehyde was added for cross linking and stirred for another 15 minutes. 
Thereafter, 250ul of each solution was immediately transferred to each microwell of lab-on-a-
chip device avoiding gelation prior to transferring. Gelatin-chitosan scaffolds were fabricated by 
freezing overnight at -20oC followed by lyophilization for 36 h to obtain dry, porous scaffolds. 
The scaffolds are referred to from now on as GC21, GC11, GC12 for gelatin/chitosan ratio of 
2:1, 1:1 and 1:2, respectively (G gelatin, C chitosan).  
 
3.5 Scaffold Characterization 
 
3.5.1 Fourier Transform Infrared Spectroscopy: 
The composite scaffold samples were ground into fine powder by freezing in liquid N2 for 30 
minutes. FTIR imaging of the samples was carried out by using Shimadzu/ IR Prestige 21. 1mg of 
each sample was mixed with IR-grade KBr so as to maintain 2% sample to KBr ratio. KBr pellet 
of the samples were prepared using KBr Press till 0-10 tons. Background scanning was first 
conducted using blank KBr pellet and subtracted from the sample readings. Then the samples 
were scanned in the region 400 cm-1 to 4000 cm-1 and a plot of wavenumber (cm-1) vs %T is 
prepared. 
 
3.5.2 X-Ray Diffraction: 
Sample was carefully placed in sample holder and subjected to X-ray diffraction in 2θ ranging 
from 5
o
 to 40
o
 with a step size of 0.05
o
 and scanning rate 7
o
 per minute. 
3.5.3 Microstructure analysis: 
Surface morphology of the scaffolds was examined by field emission scanning electron 
microscope (NOVA NANOSEM). The lyophilized scaffolds were cut with a razor blade to 
expose the inner surfaces and mounted on specimen stubs containing two-sided carbon tape. The 
samples were coated with gold particles in a sputter coater, FESEM images of the scaffolds were 
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acquired at an operating voltage of 20 kV. Average pore size of the scaffolds was measured by 
determining the average of random 25 pores using ImageJ software. 
3.5.4 Swelling Study 
Swelling ability of the scaffolds was studied by placing in phosphate buffered saline (PBS), pH 
7.4 at 37
◦
C. The initial dry weight of the scaffolds were noted as W1. The wet weight (Ws) of the 
scaffold was noted by weighing it while excess water was blotted out with absorbent paper. Wet 
weight was recorded at predetermined time points and noted as W2. Swelling ratio was 
calculated using the following equation:     
Swelling ratio (%) = (W2 −W1)/W1 × 100 
where W2 is the wet weight of the scaffolds and W1 is the initial dry weight of the scaffolds. 
 
3.5.5 Biodegradation Kinetics 
Biodegradation of the scaffolds was studied in-vitro by incubating the scaffolds in PBS (pH 7.4) 
at 37
◦
C containing 1 ug/ml hen egg lysozyme. The control system included scaffolds incubated 
in PBS without enzyme. At predetermined time-periods, the scaffolds were removed from the 
PBS solution containing enzyme, washed with Millipore water and lyophilized for 48 h. The 
extent of in vitro biodegradation was expressed as a percentage of the remaining weight of the 
dry scaffolds after enzyme treatment. Percentage biodegradation was determined using the 
equation: 
Biodegradation (%) = (Wd/W0) × 100  
where W0 is the initial dry weight of the scaffold and Wd is the dry weight of the degraded 
scaffold recorded at predetermined time points. 
 
3.5.6 Biocompatibility study: 
 
i)  Pre-culture Scaffold Preparation: 
Scaffolds were neutralized by immersing in 0.1M Glycine for 1 h to remove acetic acid, followed 
by washing three times with PBS (pH 7.4). Then the scaffolds were sterilized by exposure to UV 
light for 1 h. Scaffolds were further sterilized with 70% (v/v) ethyl alcohol for 1 h followed by 
washing three times with PBS to remove ethanol. Scaffolds were then equilibrated in complete 
medium for 1 h before cell culture. 
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ii)  Cell seeding and culture on scaffolds:  
Media was removed and HaCaT cells were seeded on the scaffold at required cell density. The 
seeded constructs were incubated in a humidified incubator for cell growth and proliferation. 
MTT assay was used to access biocompatibility of the scaffolds.  
 
MTT Assay: 
MTT assay is used for determining cell viability and cell proliferation and/or effect of cytotoxic 
agent. It is based on the quantitative measurement of extracellular reduction of yellow colored 
water soluble Tetrazolium dye 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium bromide 
(MTT) to insoluble formazon crystals by metabolically active cells. The reduction is mediated by 
mitochondrial enzyme lactate dehydrogenase. When dissolved in a solubilization solution such 
as dimethylsuphoxide (DMSO), these formazon crystals exhibit purple color. The intensity of 
this color is proportional to the number of viable cells and can be measured 
spectrophotometrically at 570nm. MTT Reagent is added to a final concentration of 10% of the 
total volume. 
 
iii)  SEM of cell seeded scaffold: 
Scanning electron micrograph of cell seeded scaffold was taken after fixing the cells. Fixing was 
done by immersing the cell seeded scaffolds in SEM buffer containing 2.5% glutaraldehyde for 
2h. Scaffolds were critically dried using graded ethanol treatment (30%, 50%, 70%, 90%, 95%, 
100% ethanol) each of 15 minutes duration.  
 
Statistical analysis: All experiments were performed in triplicates for each sample and data is 
expressed as mean ± standard deviation (SD) for n=3. 
 
3.6 Suitability of gelatin-chitosan scaffold as cancer tissue mimic 
Scaffolds were neutralized and sterilized using the same afore-mentioned protocol. HeLA cells 
were seeded on the scaffold at a cell density (5x10
4
). The seeded constructs were incubated in a 
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humidified incubator for 2 days to allow cell growth and proliferation within the porous scaffold. 
Stock solutions (1mg/ml) of two drugs - Fluorouracil (5-FU) and Cisplatin was prepared in PBS.  
 
3.6.1 Drug Treatment 
The cell seeded scaffold constructs were analyzed for their chemotherapeutic sensitivity to 5-FU 
and Cisplatin at two different concentrations (10ug/ml, 50ug/ml) for each drug. Effect of these 
cytotoxic agents on cell viability and proliferation within the scaffold was accessed by MTT 
assay. The control system included HeLa cells directly cultured in the microwell at the same cell 
density as seeded on the scaffold.  
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4.1 FTIR analysis: 
The inter-molecular interaction can be determined by FTIR when two polymers are blended 
together to form a scaffold. In case of GC blends, FTIR analysis was conducted by identifying 
absorption bands  associated with the vibrations of functional groups present in the 
macromolecules. Exactly similar FT-IR spectra was obtained from the three blends: GC 21, GC 
11, GC 12. Hence, we can state that varying the ratio of gelatin and chitosan has no effect on the 
molecular structure of GC scaffolds. 
 
Fig. 7 FTIR spectra of gelatin-chitosan scaffolds 
4.2 XRD analysis: 
Many papers have reported that gelatin shows a peak at 7
o
 and a broad amorphous peak at 
around 21
o
. Chitosan is characterized by two crystalline peaks at 2θ = 14O and 20o. From the X-
ray diffractogram, we can observe that in gelatin-chitosan composite scaffold, the crystalline 
peak of chitosan at 2θ = 14O is no more seen and the crystalline peak at 2θ = 20o seems to get 
merged with broad amorphous peak of gelatin. A small crystalline peak is obtained at 2θ = 31o in 
all the three compositions. All the three compositions have similar XRD spectra. Hence, we can 
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state that varying the composition of gelatin & chitosan has no effect on the atomic structure of 
composite amorphous scaffold.  
 
Fig. 8 XRD pattern of gelatin-chitosan scaffolds 
4.3 Microstructure analysis: 
Surface morphology of gelatin-chitosan scaffold was investigated using scanning electron 
microscopy to identify any changes in basic microarchitecture due to the variation in gelatin –
chitosan composition. It was found that all three types of scaffold have porous structure with 
apparent interconnectivity. The average pore diameter of GC 21 was found 160 ± 17 µm. Same 
for GC 11 and GC 12 were found 118 ± 21µm and 102 ± 09µm respectively. The average pore 
diameter seems to decrease with the increase chitosan content. Cell culture on 3D matrix is 
concerned with the pore size and interconnectivity among the pores in the scaffold is one of the 
key factors because it greatly influence the nutrient transport process. Moreover, it is observed 
that cells has some prerequisite of pore diameters which depends on the nature of the cells for 
successful growth in vitro 3D environment. From that point of view GC 21 seems to be the 
promising one for three dimensional cell culture. 
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       Fig. 9 Scanning electron micrograph of gelatin-chitosan scaffolds. [A] GC 21 [B] GC 11 [C] GC 12 
4.4 Swelling Study:  
Among all three scaffolds GC 21 showed highest water retaining capacity. The ability of the scaffold to 
swell plays an important role during the in-vitro culture studies. Swelling enhances the pore 
diameter thus helps increasing surface area to volume ratio inside the scaffold which facilitates 
three dimensional cell attachment and growth. High swelling also ensures maximum availability 
of nutrients inside the scaffold.   
 
Fig. 10 Swelling kinetics of gelatin-chitosan scaffolds. Values are mean ±S.D. (n=3) 
4.5 Biodegradation Kinetics: 
All gelatin-chitosan scaffold degraded in the lysozyme containing PBS as evident from their 
weight loss which counts up to 45% of the initial dry weight. Biodegradation of gelatin- chitosan 
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scaffolds are mainly due to the dissolution of gelatin in PBS which is further augmented by 
lysozyme mediated degradation of chitosan. Though GC 21 showed highest degradation with in 
24 hrs (21.73%) but its overall degradation (38.9%) was less compared to other compositions 
after 7 days. 
 
Fig. 11 Biodegradation kinetics of gelatin-chitosan scaffolds. Values are mean ±S.D. (n=3) 
 
4.6  Biocompatibiliy: 
Highest cell proliferation was observed in case GC 21 in comparison to other compositions and 
2D control system as measured by MTT assays. GC 21 scaffold is found to be non-toxic and 
cytocompatible to HaCaT cells. Healthy conditions of the cells cultured on the scaffold were 
further confirmed by analyzing SEM micrograph of cell seeded scaffold. Micrograph revealed 
that cells were three dimensionally organized inside the scaffold. 
Experimental results revealed that scaffold with high gelatin content (GC 21) is more reliable 
than GC 11 and GC 21 as it posses  higher pore size, high water uptake capability and controlled 
biodegradation. GC 21 was also found to be compatible with HaCaT cells. Considering the 
physical and functional properties, GC 21 was chosen as a model scaffold for in vitro cell based 
analysis. 
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Fig. 12  Biocompatibility of gelatin-chitosan   
scaffolds with HaCaT cells 
Fig. 13 SEM micrograph of HaCaT cells  
seeded on GC 21 scaffold      HaCaT cells seeded on GC 21 scaffold 
 
4.7 Scanning Electron Micrograph of HeLa cells in 2D and 3D: 
Distribution of cells within the scaffold was visualized by SEM. We already know that cells 
cultivated directly on tissue culture plates considerably differ in their morphology, cell-cell, cell-
matrix interactions from those cells growing in 3D microenvironment. 3D presentation of 
adhesive ligands by biomaterials influences spindle orientation. HeLa cells on 2D showed flat 
and elongated morphology.  
 
         
Fig. 14 Scanning Electron Micrograph of HeLa 
cells in 2D   
Fig. 15 Scanning Electron Micrograph of           
HeLa cells seeded on GC 21 scaffold      HaCaT cells seeded on GC 21 scaffold 
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4.8  Drug sensitivity: 
Comparison of 3D and 2D results revealed that, for the same cell seeding density and drug 
regimen, percentage cell death is more in case of 2D model compared to cell seeded scaffold 
construct. A significant dose dependent response was obtained after 24 h exposure to 5FU and 
Cisplatin. HeLa cell seeded scaffolds were more resistant to 5FU and Cisplatin treatment, 
suggesting poor drug diffusion through the scaffold and lack of complete bioavailability of drug 
to target cancer cells. Cytotoxicity profile and difference in drug susceptibility between 2D and 
3D model is higher in case of cisplatin compared to 5FU which prooves that Cisplatin is a more 
effective & potential drug candidate.  
 
Fig. 16  Percentage cell death in response to varying doses of 5-Fluorouracil and Cisplatin 
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5.1 Hanging Drop Technique 
 
Hanging drop technique uses cell suspension droplets hanging from the underside of the lid of 
tissue culture dish. It utilizes gravity enforced aggregation of cells into a single cluster, which 
then forms into a spheroid [13]. Due to hydrophilicity of the plate and surface tension of the cell 
suspension droplet, the drop would hang from the bottom surface of the plate, thereby forming a 
meniscus in the centre region of the drop. Hanging drop technique is a simple, cost-effective 
method that allows formation of uniform spheroids of defined size. However, maintaining 
spheroids in hanging drops requires regular change of medium which is time consuming and 
inconvenient. Major drawback to using spheroids for large-scale screening is the cumbersome 
transfer step. 
 
           
         Fig. 17        Cell Aggregation                      Compaction                   Microtissue Formation    
 
5.2 Microtissue formation  
Hanging Drop method was used for making HeLa microtissues. HeLa cells were grown via the 
hanging drop method over a 6 day experimental period. 25 μL of cell suspension of required cell 
density was pipetted into a petri dish. Then the tissue culture plate was turned upside down and 
incubated at 37
o
C, 5% CO2. Gravity driven self assembly of cells results in the formation of 
microtissue in the centre of the drop. Microtissues were successfully produced in a reproducible 
manner following this method. 
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Fig. 18 Hanging Drop Culture 
 
5.3 Microtissue Monitoring and optimization of Cell number 
 
Optimal number of cells required for the formation of microtissue of desired size and 
compactness was determined by varying cell seeding density, from 10
3
 cells to 10
6
 cells. 
Microtissue integrity was visualized by phase contrast microscope, which can also be used for 
recording microtissue volume growth kinetics. Images for quantitative analysis of the size 
distribution and shape of HeLa microtissue were routinely captured by phase contrast 
microscopy at day 4, day 5 & day 6 after seeding. Compactness profile and size kinetics of 
microtissue from day 4 to day 6 was plotted using ImageJ. 
 
5.4 Seeding Microtissue on the scaffold: 
Scaffolds were neutralized and sterilized using the protocol mentioned in 3.5.6 (i). Microtissue 
transfer was achieved by direct pipetting using a tip whose top portion has been removed so as 
not to disrupt the microtissue by shear or stress. Individual microtissues were retrieved from the 
petri dish and then gently pipetted into fresh culture dish (35mm dia). Three intact HeLA 
microtissues were seeded on each scaffold. The seeded constructs were incubated in a humidified 
CO2 incubator for 2 days to allow microtissue growth and proliferation within the 3D 
microenvironment of the porous scaffold. Viability of microtissue seeded scaffold constructs was 
accessed by MTT assay. The control system included (i) HeLa cells directly cultured in the 
microwell at the same cell density as present in the microtissue (ii) HeLa microtissue directly 
cultured in the microwell (iii) Hela cells directly seeded on the scaffold at  the same cell density 
as present in the microtissue. Cell proliferation in each case was plotted using 2D monolayer 
system as reference and comparative analysis was performed.  
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5.5 Drug Susceptibility: 
To validate the 3D cancer model, it is necessary to screen its chemotherapeutic susceptibility to 
anticancer drugs. Microtissues were seeded on the scaffold and their chemotherapeutic 
sensitivity was evaluated using 5-FU and Cisplatin at a concentration of 50ug/ml for each drug. 
Effect of these cytotoxic agents on cell viability within the microtissue present in the 3D 
microenvironment of scaffold was accessed by MTT assay using previously described control 
systems. Percentage cell death recorded with two drugs was plotted and comparative analysis 
was performed. 
 
5.6. Cryopreservation: 
The word Cryopreservation is composed of two words "cryo" and "preservation". "Cryo" 
meaning cells or tissue and "preservation" meaning to the act of preserving something. It is a 
process in which cells or any other substances which might be damaged due course of time or 
due to chemical reactivity are preserved by cooling to ultra low temperatures. At very low 
temperatures, the possibility of damage due to enzymatic or chemical activity is effectively 
stopped. This is attained without causing additional damage due to the formation of ice crystals 
during freezing. Advantages of cryopreservation are listed as follows: 
  Lowered risk of contamination by microorganisms 
  Lowered risk of cross contamination of cells by other cell lines 
  Lowered risk of morphological and genetic changes 
  Cost effective  
 
 Temperature: Sub-zero temperatures provide indefinite longevity to the cells. However, it is 
difficult to predict the actual effective life. Boiling point of liquid nitrogen (−196 °C or 77 K or 
−321 °F), the, is the preferred temperature for cryogenic storage. When adequate cryogenic 
facilities are unavailable, refrigerators and extra-cold freezers are often used for cooling. 
Generally ultra-cold liquid nitrogen is required for successful cryopreservation in order to 
virtually stop all biological and enzymatic activity.  
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Cryoprotective agents: Cryoprotective agents have the ability to enter cells and to prevent 
dehydration and formation of ice crystals in the cytoplasm of the cells, which can 
cause destruction of cell organelles and cell death. Two common cryoprotective agents 
are dimethy suphoxide (DMSO) and glycerol. Glycerol is used for cryoprotection of RBC's, and 
DMSO is most commonly used for protection of other cells and tissues.  
 
5.6.1 Cryopreservation of Microtissue seeded scaffold construct: 
Evaluation of anticancer drug efficacy in in-vitro 3D cancer model necessitates careful 
investigation of its cryopreservation performance. Cryopreservable 3D cancer model plays a very 
important role in terms of its “ready-to-use” application in drug screening after resuscitation. We 
investigated whether microtissue seeded scaffold construct could be cryopreserved for “ready-to-
use” applications. The cryopreservable and tumorigenic 3-D cancer model offers an effective 
platform for drug screening. Lot of research work has been undertaken to ensure successful 
cryopreservation and resuscitation of cancer models. Successful cryopreservation is based on the 
basic principle of a slow freeze and thaw cycle. Although the requirements of different cells 
would vary, the general guidelines are: cells must be cooled at a rate of –1°C to –3°C per minute 
and quickly thawed by incubating the cryovials in a 37°C water bath for 3-5 minutes. If this is 
followed then most cells should be cryopreserved successfully.   
 
5.6.2 Cryopreservation Protocol 
 
i) Preparation of Cryopreservation medium: 
Cryopreservation  medium should have the same formulation as that used to cultivate cells with 
the addition of FBS in case of serum-free cultures or with the increase in the concentration of 
FBS, but to a final concentration of not more than 20%. FBS performs the role of binding toxic 
materials which may be released if some cells are lysed during the freezing or thawing process. 
Using a cryopreservative agent is a must requirement. Either of the two - DMSO or glycerol 
can be used, primary choice being sterile DMSO. The following composition of 
cryopreservation medium was standardized for use in all our experiments: 
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                                        Dimethy Sulphoxide (DMSO)     10% 
                                        Culture Media (MEM)                  20% 
                                        Fetal Bovine Serum (FBS)            80% 
 
ii) Freezing: 
Microtissue seeded scaffold was immersed in cryovials, each containing 2 ml cryopreservation 
medium. Vials were first placed in 4
o
C freezer for 30 minutes and then in -20
o
C for 2 h and 
subsequently in -80
o
C freezer for 4 h. The vials will freeze slowly after which they were directly 
transferred to liquid nitrogen storage tank. 
 
iii) Thawing cryopreserved system: 
After 24 h, microtissue seeded scaffold system was resuscitated/ retrieved quickly to obtain the 
best possible viability. Once the cryovial was removed from liquid nitrogen tank, it was directly 
submersing in pre-warmed distilled water at 37
o
C for 1-2 minutes. Cell viability was assessed by 
MTT assay. Control system used is microtissue seeded scaffold cultivated in a humidified 
incubator (37
o
C, 5% CO2) for 48 h. 
 
Key points: 
 Cryopreservation medium must be prepared fresh each time. 
 Cryoprotective agents must always be used at an appropriate concentration so as to avoid 
viability issues.  
 Cryoprotective agents tend to rapidly oxidize or absorb potentially toxic materials from the 
air. Hence, they must be used fresh each time. Large volumes should not be procured.  Reagent 
bottle must not be continuously opened and closed.  
 Personal protective equipments must be wore at all times while handling cryovials from 
liquid nitrogen tank. Liquid nitrogen will expand drastically around 700 times during the 
warming process. Hence, care must be taken while removing cryovials from liq N2 storage tank 
as there can be chance of explosion, if liquid nitrogen has entered the cryovial. Cryovials once 
removed from liquid nitrogen tank must be quickly transferred to 37
o
C water bath.  
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6.1. Optimization of Cell number: 
 
Fig.19  Phase contrast images of Microtissue at different cell density per drop 
 
The process of embryonic development is thermodynamically regulated during which specific 
number of cells are involved in complex cell-cell adhesion thereby forming morula. A similar 
mechanism is observed in microtissue formation. Microtissue size can be fine-tuned by changing 
the seeding density of cells. With lesser number of cells (10
3
 and 10
4
), microtissue formed is 
loosely bound and not compact. Increasing the cell density to 10
5
 cells per drop, yielded a 
compact microtissue with a central dense core. However with 10
6
 cells, a loosely bound 
microtissue was obtained. Hence, we could conclude that 10
5
 cells is the optimal cell density 
required for the formation of a uniform pool of compact microtissues. 10
5 
HeLa cells 
spontaneously aggregate into viable 3D microtissue or microscale spheroids when cultured in 
environments where cell-cell interactions dominate over cell-substrate interactions. 
 
Fig.20 Approximately 32 hanging drops deposited and grown under a 15-cm dish lid 
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6.2 Microtissue Compactness and Area growth kinetics: 
Spheroid morphology was routinely monitored from day 4 to day 6. It was observed that 
micotissue diameter continued to increase until day 6 with the loss of tight packing between the 
cells. Surface plots were drawn using ImageJ to visualize the compactness of microtissue. On 
day 4, cells were tightly bound to each other, and individual cells were no more observed. With 
increase in time, the aggregates became less denser and its diameter kept increasing. Longer 
culturing time (>5 days) lead to a significant loss of compactness and increase in the  microtissue 
diameter. Size of the microtissue increased as a function of time. 4 days of culture produced 
uniformly sized HeLa microtissues with an average size of 2mm, at the initial seeding density of 
10
5
 cells/mL.  
 
5  
Fig. 21 Phase Contrast Images and Compactness profile of microtissue at day 4, 5 and 6 
Day 4 
Day 5 
Day 6 
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Area growth kinetics revealed the exponential increase in the area of microtissue over a 7 day 
experimental period. Optimal micotissue formed after 4 days of culture. Hence, aggregated HeLa 
microtissues were obtained from 10
5
 cells after 4 days of culture.   
 
 
Fig. 22 Area growth profile of microtissue from day 4 to day 6 
 
6.3. Viability Assay of Microtissue seeded scaffold  
 
Fig. 23 Cell proliferation index of microtissue seeded scaffold construct compared to control system 
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Simply, HeLa cell seeded scaffold does not recapitulate the intimate cell-cell architecture found 
in normal tissue. Rather, it closely approximates a culture system in which single cells are 
loosely dispersed within a 3D ECM meshwork. 3D microtissue seeded scaffold model showed 
higher viability compared to control counterparts. This is due to an intricate network of cell-cell 
interactions under the influence of native ECM like scaffold. Porous nature of the scaffold 
mimicking native ECM provides 3D microenvironment to the in-vivo like tumor masses, the 
microtissues  which progressively grow and hence show higher viability.  
 
6.4 Anticancer drug cytotoxicity study: 
 
Fig. 24 Percentage cell death of microtissue seeded scaffold construct compared to control system and 
theoretical predictions. 
 
Cytotoxicity of 5FU and Cisplatin was evaluated in in-vitro 3D tumor model with microtissue 
encapsulated in the scaffold and compared to control system. Chemotherapeutic sensitivity of the 
cancer cells varies with microenvironment especially when moving from 2D monolayer to 3D 
solid tumor like environment. Comparison of 2D and 3D results revealed that upon treatment 
with 5-FU and Cisplatin, percentage cell death in 3D model was approximately 58% and 62% 
respectively in comparison to approximately 76% and 80% respectively in 2D. 3D microtissues 
were more chemoresistant than 2D monolayer due to the presence of of quiescent cells in 
microtissue. This resistance to therapeutics in case of 3D model is thought to be associated with  
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the three dimensional organizations of cells within the matrix and poor diffusion of drug 
molecules through the microtissue and scaffold. Because the proposed 3D tumor model bears 
close resemblance to in-vivo human cancer tissues both morphologically and physiologically, the 
toxicity derived from this is more accurate than the false positive cytotoxicity results obtained in 
2D monolayer cells.  
 
6.5 Cryopreservation performance: 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 25 MTT Assay of cryopreserved  microtissue seeded scaffold construct compared to control system 
which was not cryopreserved 
 
Compared to control system which was not cryopreserved, 76% cell viability was attained after 
resuscitating cryopreserved 3D model. This is significant and implies that long term storage of 
our system is feasible for ready to use drug screening applications. Viability can further be 
increased by carefully monitoring the process of controlled rate freezing and thawing.  
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CONCLUSION 
 
3D cancer models with in vivo like characteristics of cell–cell, cell–matrix interactions are 
powerful tools for drug screening. Proposed 3D cancer model of microtissue encapsulated in 
gelatin-chitosan scaffold closely mimics in-vivo tumor and acts as a promising screening tool for 
various existing and novel cancer therapies, including nanoparticles, liposomes, and nonviral 
gene delivery. Anti-proliferative effect of anticancer drugs in 3D model was significantly lower 
compared to 2D monolayer. Direct correlation between the results of drug effects observed in 
our model  to  the  theoretically predicted in-vivo efficacy establishes  the  usefulness  of  our  
model  in  drug  discovery and development. It is physiologically more relevant than 2D systems 
and animal models. The proposed model offers an economically advantageous in-vitro platform 
for testing drug delivery systems. The model is convenient to be handled and easy for any lab to 
maintain or reproducibly manufacture. It's impact lies in the benefits it offers for investigating 
the chemotherapeutic efficiency of anticancer therapeutics with relatively low costs.  
 
Key Features of the proposed model: 
                                       1. Highly controllable and reproducible 
                                       2. Relatively low cost 
                                       3. High in-vivo like characteristics and predictivity 
                                       4. More physiologically relevant than 2D monolayer and spheroid model 
                                       5. Cryopreservable 
                                       6. Ready-to-use, no mixing and preparation method 
                                       7. Easy for any lab to maintain & readily use for screening new drugs 
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FUTURE WORK 
 
1. Monitoring and understanding the process of tumor vascularization - angiogenesis. 
 
2. Visualizing the surface morphology of microtissue by Scanning Electron Microscopy. 
 
3. Visualizing the internal structure of microtissue by Transmission Electron Microscope. 
 
4. Live/dead assay of HeLa microtissue by flow cytometry  
 
5. Cell cycle analysis of microtissue and cells in monolayer by flow cytometry. 
 
6.  Visualizing the penetration behavior of anticancer therapeutics into individual microtissue 
and distribution of drug in the microtissue seeded scaffold construct. 
7. Examining drug uptake kinetics in individual microtissue as a function of time which would 
allow and determination of effective diffusion coefficients. 
8. Prepare microtissues comprising multiple cell types - heterogeneous tumor/stromal cell co-
culture (fibroblast cells, immune cells etc.) to mimic in-vivo tumor heterogenity. 
9. Upgrade the sensitivity, and compatibility of developed lab-on-a-chip device with high-
throughput screening (HTS) instruments. 
10. Optimize cryopreservation to improve viability post resuscitation.  
 
11. Study cellular migration and tumor dissemination within the 3D microtissue seeded scaffold 
constructs. 
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